ASX:CDY

Cellmid Competitors

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Cellmid (ASX:CDY) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying CDY stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Cellmid, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Cellmid vs. (CHV) Stock

Cellmid (ASX:CDY) and (CHV) (CNSX:CHV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Cellmid and (CHV)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellmid	N/A	N/A	N/A
(CHV)	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Cellmid and (CHV), as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellmid	0	0	0	0	N/A
(CHV)	0	0	0	0	N/A

Valuation and Earnings

This table compares Cellmid and (CHV)'s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellmid	$6.61 million	0.00	$-9,082,946.59	A($0.05)	N/A
(CHV)	N/A	N/A	N/A	N/A	N/A

(CHV) has lower revenue, but higher earnings than Cellmid.

Summary

Cellmid beats (CHV) on 1 of the 1 factors compared between the two stocks.

Cellmid vs. (DDXS) Stock

(DDXS) (OTCMKTS:DDXS) and Cellmid (ASX:CDY) are both health technology companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares (DDXS) and Cellmid's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(DDXS)	N/A	N/A	N/A
Cellmid	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for (DDXS) and Cellmid, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(DDXS)	0	0	0	0	N/A
Cellmid	0	0	0	0	N/A

Earnings and Valuation

This table compares (DDXS) and Cellmid's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(DDXS)	N/A	N/A	N/A	N/A	N/A
Cellmid	$6.61 million	0.00	$-9,082,946.59	A($0.05)	N/A

(DDXS) has higher earnings, but lower revenue than Cellmid.

Summary

Cellmid beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Cellmid vs. (PREV) Stock

(PREV) (CNSX:PREV) and Cellmid (ASX:CDY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares (PREV) and Cellmid's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(PREV)	N/A	N/A	N/A
Cellmid	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for (PREV) and Cellmid, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(PREV)	0	0	0	0	N/A
Cellmid	0	0	0	0	N/A

Earnings and Valuation

This table compares (PREV) and Cellmid's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(PREV)	N/A	N/A	N/A	N/A	N/A
Cellmid	$6.61 million	0.00	$-9,082,946.59	A($0.05)	N/A

(PREV) has higher earnings, but lower revenue than Cellmid.

Summary

Cellmid beats (PREV) on 1 of the 1 factors compared between the two stocks.

Cellmid vs. (TNGN) Stock

(TNGN) (OTCMKTS:TNGN) and Cellmid (ASX:CDY) are both health technology companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares (TNGN) and Cellmid's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(TNGN)	N/A	N/A	N/A
Cellmid	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for (TNGN) and Cellmid, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(TNGN)	0	0	0	0	N/A
Cellmid	0	0	0	0	N/A

Earnings and Valuation

This table compares (TNGN) and Cellmid's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(TNGN)	N/A	N/A	N/A	N/A	N/A
Cellmid	$6.61 million	0.00	$-9,082,946.59	A($0.05)	N/A

(TNGN) has higher earnings, but lower revenue than Cellmid.

Summary

Cellmid beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Cellmid vs. 138267 (COM.TO) Stock

138267 (COM.TO) (TSE:COM) and Cellmid (ASX:CDY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for 138267 (COM.TO) and Cellmid, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
138267 (COM.TO)	0	0	0	0	N/A
Cellmid	0	0	0	0	N/A

Profitability

This table compares 138267 (COM.TO) and Cellmid's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
138267 (COM.TO)	N/A	N/A	N/A
Cellmid	N/A	N/A	N/A

Earnings and Valuation

This table compares 138267 (COM.TO) and Cellmid's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A
Cellmid	$6.61 million	0.00	$-9,082,946.59	A($0.05)	N/A

138267 (COM.TO) has higher earnings, but lower revenue than Cellmid.

Summary

Cellmid beats 138267 (COM.TO) on 1 of the 1 factors compared between the two stocks.

Cellmid vs. 17031 Stock

Cellmid (ASX:CDY) and 17031 (CNSX:MYM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Cellmid and 17031, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellmid	0	0	0	0	N/A
17031	0	0	0	0	N/A

Profitability

This table compares Cellmid and 17031's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellmid	N/A	N/A	N/A
17031	N/A	N/A	N/A

Valuation and Earnings

This table compares Cellmid and 17031's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellmid	$6.61 million	0.00	C$-9,082,946.59	A($0.05)	N/A
17031	N/A	N/A	N/A	N/A	N/A

17031 has lower revenue, but higher earnings than Cellmid.

Summary

Cellmid beats 17031 on 1 of the 1 factors compared between the two stocks.